



## Hany Elmariah

Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)

Medicine - Blood & Marrow Transplantation

### CLINICAL OFFICE (PRIMARY)

- **Stanford Cancer Center**

875 Blake Wilbur Dr Clinic F

MC 6560

Stanford, CA 94305

**Tel** (650) 498-6000      **Fax** (650) 498-6919

### Bio

---

#### BIO

Dr. Hany Elmariah is an Associate Professor in the Division of Blood and Marrow Transplantation and Cellular Therapy at Stanford University. Dr. Elmariah earned his MD and his MS in Biomedical Engineering at the University of Florida. He completed an Internal Medicine Residency at Duke University. Dr. Elmariah then completed a Hematology and Oncology Fellowship at Johns Hopkins University, where he also served as Chief Fellow. He then was a faculty member at the Moffitt Cancer Center before joining the faculty at Stanford University. Dr. Elmariah's clinical focus is allogeneic transplant for myeloid malignancies including acute myeloid leukemia, myelodysplastic syndromes, and myeloproliferative neoplasms. His research is focused on haploidentical and mismatched unrelated donor blood and marrow transplantation and novel cellular therapies for myeloid malignancies.

#### CLINICAL FOCUS

- Hematology
- Oncology
- Bone Marrow Transplant
- Cellular Therapy
- Leukemia

#### ACADEMIC APPOINTMENTS

- Associate Professor - University Medical Line, Medicine - Blood & Marrow Transplantation

#### PROFESSIONAL EDUCATION

- Board Certification: Medical Oncology, American Board of Internal Medicine (2018)
- Board Certification: Hematology, American Board of Internal Medicine (2018)
- Fellowship: Johns Hopkins Hematology and Medical Oncology Fellowship (2018) MD
- Board Certification: Internal Medicine, American Board of Internal Medicine (2014)
- Residency: Duke University Internal Medicine Residency (2014) NC

- Medical Education: University of Florida College of Medicine (2011) FL

## Research & Scholarship

---

### CLINICAL TRIALS

- Phase I Donor Grafts Derived From Orca-Q w/GVHD Prophylaxis in MA-AlloCHT in Hematologic Malignancies, Recruiting

## Publications

---

### PUBLICATIONS

- **Superior Chronic GVHD-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.** *Transplantation and cellular therapy*  
Molina, A., Bubb, Q. R., Srinagesh, H. K., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, et al  
2026
- **Posttransplant MRD monitoring by TP53 duplex sequencing with APR-246 + azacitidine maintenance predicts outcomes.** *Blood advances*  
Sallman, D. A., McLemore, A. F., Komrokji, R., Elmariah, H., Kuykendall, A. T., Bejanyan, N., Chan, O., Faramand, R., Pidala, J., Yoder, S. J., Perez, L., Nishihori, T., Padron, et al  
2026; 10 (4): 1053-1057
- **Differential effects of two common GVHD prophylaxis regimens on the gut microbiome: Results from the BMT CTN 1801 study.** *bioRxiv : the preprint server for biology*  
Wirbel, J., Saber, W., Martens, M. J., Peled, J. U., Andermann, T. M., Fei, T., Brooks, E. F., Doyle, B., Pincus, N. B., Jenq, R. R., Bar, M., Bolaños-Meade, J., Bratrude, et al  
2026
- **Superior Long-Term Survival with Fludarabine-Melphalan RIC Regimen in Older AML/MDS Patients: A Propensity Score Analysis of CIBMTR Data**  
Kongtim, P., Portuguese, A. J., Soyoung, K., Peterson, A., Elmariah, H., Muffly, L. S., Juckett, M. B., Grunwald, M., Nawas, M., Bejanyan, N., Jain, T., Bachanova, V., Bi, et al  
ELSEVIER SCIENCE INC.2026: S53-S54
- **Effect of GVHD Prophylaxis on Renal Function and Survival Outcomes in Allogeneic Hematopoietic Cell Transplant Patients with Pre-Existing Renal Impairment**  
Amisha, F., Schmitz, J., Vazquez-Martinez, M., Caprice, T., Kim, J., Naqvi, S., Torres, N., Mishra, A., Mirza, A., Perna, F., Perez, L., Ramlal, R., Faramand, et al  
ELSEVIER SCIENCE INC.2026
- **Characterization and Outcomes of Switching Tacrolimus to Sirolimus in Patients with Transplant-Associated Thrombotic Microangiopathy**  
Kennedy, V. E., Lauer, M., Shiraz, P., Arai, S., Johnston, L., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Lowsky, R., Meyer, E. H., Mikkilineni, L., Muffly, et al  
ELSEVIER SCIENCE INC.2026
- **Patient Characteristics, Toxicity, and Response after Real World Administration of Obecabtagene Autoleucl and Brexucabtagene Autoleucl for Relapsed Acute Lymphoblastic Leukemia: A Rocca Analysis**  
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, A., Arai, et al  
ELSEVIER SCIENCE INC.2026: S27
- **Baseline IPSS-M vs Pretransplant Risk Downstaging as Prognostic Determinants in MDS Undergoing Allogeneic Transplantation.** *Blood advances*  
Aguirre, L. E., Kim, H. T., Elmariah, H., Frumm, S. M., Kelkar, A. H., Ho, V. T., Gooptu, M., Koreth, J., Shapiro, R. M., Romee, R., Nikiforow, S., Antin, J. H., Soiffer, et al  
2026
- **Post-transplant cyclophosphamide vs tacrolimus/methotrexate: Improved GRFS, reduced NRM, and less severe GVHD in myeloablative HLA-matched allogeneic transplantation**  
Molina, A., Bubb, Q., Yee, R., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, E., Mikkilineni, L., Lowsky, et al

ELSEVIER.2025: 2494-2495

- **Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts Outcomes.** *Blood advances*  
Sallman, D. A., McLemore, A. F., Komrokji, R. S., Elmariah, H., Kuykendall, A. T., Bejanyan, N., Chan, O., Faramand, R., Pidala, J. A., Yoder, S. J., Perez, L. E., Nishihori, T., Padron, et al  
2025
- **Secondary graft failure after PT-cy: Modeling a candidate risk assignment biomarker based on lymphocyte reconstitution. Results from the BMT CTN 1801 study**  
Omdahl, K., Siegel, S., Dong, J., Dewolf, S., Hebert, K., Neuberg, D., Schichter, I., Albanese, A., Keskula, P., Cagnin, L., Applegate, K., Bar, M., Chhabra, et al  
ELSEVIER.2025: 4198-4199
- **Patients with TP53-mutated AML/MDS without complex or monosomal karyotype can achieve durable survival benefits with allogeneic HCT**  
Jeyakumar, N., Torres, N., Godbole, S., Yamamoto, F., Zhang, B., Arai, S., Bharadwaj, S., Dahiya, S., Elmariah, H., Frank, M., Hosoya, H., Johnston, L., Meyer, et al  
ELSEVIER.2025: 2525-2526
- **Combined TCR-seq and single-cell RNA-seq reveal distinct origins for antiviral immunity after post-transplant cyclophosphamide and tac/MTX gvhd prophylaxis: Results from the BMT CTN 1801 study**  
Siegel, S., Dewolf, S., Schmalz, J., Winn, N., Kaminski, J., Bien, S., Sanders, C., Robins, H., Zavistaski, J., Schichter, I., Steinberg, L., Applegate, K., Bar, et al  
ELSEVIER.2025: 818-819
- **Superior efficacy and persistence of Orca-T-allogeneic CAR19/22 versus autologous CAR19/22 in high-risk adult B-ALL**  
Molina, A., Shiraz, P., Kanegai, A., Fraser, A., Kordek, D., Wagner, C., Srinagesh, H., Danley, L., Ramakrishnan, A., Daghigh, H., Huang, Y., Dhapola, G., Siddiqui, et al  
ELSEVIER.2025: 514-515
- **Predictors of outcomes to allogeneic hematopoietic cell transplantation (allo-HCT) for TP53 mutant myelodysplastic neoplasms (MDS) and acute myeloid leukemia (AML) patients and impact of hypomethylating agent (HMA) maintenance therapy**  
Wagstaff, C., Mishra, A., McLemore, A., Chan, O., Shallis, R., Pidala, J., Kuykendall, A., Reynolds, S., Elmariah, H., Al Ali, N., Torres, N., Xie, Z., Perez, et al  
ELSEVIER.2025
- **Superior long-term outcomes with fludarabine and melphalan reduced intensity regimen in older AML/MDS patients undergoing allogeneic stem cell transplantation: An analysis of CIBMTR data**  
Kongtim, P., Portuguese, A., Kim, S., Peterson, A., Elmariah, H., Muffly, L., Juckett, M., Grunwald, M., Nawas, M., Bejanyan, N., Jain, T., Bachanova, V., Bi, et al  
ELSEVIER.2025: 109-110
- **Impact of Obesity and Weight-Based Chemotherapy Dosing Adjustments on Outcomes of Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia.** *Transplantation and cellular therapy*  
Gaskill, E., Albanyan, O., Naqvi, S. M., Mo, Q., Belfon, A., Nishihori, T., Faramand, R., Lazaryan, A., Hansen, D. K., Khimani, F., Mishra, A., Nieder, M., Perez, et al  
2025
- **Reducing Effects of Hospital Associated Deconditioning in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation-** *CLINICAL JOURNAL OF ONCOLOGY NURSING*  
Schmitz, J., Weigl, B., Patterson, A., Kumar, A., Johansson, M., Elmariah, H.  
2025; 29 (5): 416-422
- **Hematopoietic Cell Transplantation, Version 3.2025** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Loren, A. W., Mielcarek, M., Bolanos-Meade, J., Brammer, J., Cowden, M., Di Stasi, A., El-Jawahri, A., Elmariah, H., Gundabolu, K., Gutman, J., Ho, V., Hoeg, R. T., Horwitz, et al  
2025; 23 (10)
- **Trial of Enasidenib Maintenance Post Allogeneic Hematopoietic Cell Transplant in Patients With IDH-2 Mutated AML.** *Transplantation and cellular therapy*  
Salhotra, A., Bejanyan, N., Yang, D., Mokhtari, S., Knobler, D., Park, G., Malki, M. M., Sandhu, K. S., Faramand, R., Aldoss, I., Artz, A. S., Aribi, A., Elmariah, et al

2025

- **Letermovir reduces cytomegalovirus in HLA-matched and mismatched allogeneic hematopoietic cell transplant patients receiving post-transplant cyclophosphamide.** *Bone marrow transplantation*  
Schmitz, J., Gaskill, E., Price, S., Cao, B., Kim, J., Baluch, A., Klinkova, O., Faramand, R., Mishra, A., Perez, L., Khimani, F., Lazaryan, A., Ochoa-Bayona, et al  
2025
- **Phase II Trial of Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation Conditioning With Haploidentical Donor Peripheral Blood Stem Cell Transplant.** *American journal of hematology*  
Elmariah, H., Kim, J., Gonzalez, R., DiMaggio, E., Sansil, S., Mishra, A., Faramand, R., Perez, L., Lazaryan, A., Mirza, A., Khimani, F., Liu, H., Ochoa-Bayona, et al  
2025
- **Optimal GVHD Prophylaxis.** *Advances in experimental medicine and biology*  
Elmariah, H., Bolaños-Meade, J.  
2025; 1475: 77-102
- **Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703.** *Blood advances*  
Abedin, S. M., Martens, M. J., Bolaños-Meade, J., Al Malki, M. M., Lian, Q., Runaas, L., Elmariah, H., Gooptu, M., Larkin, K., Shaffer, B. C., Loren, A. W., Solh, M. M., Alousi, et al  
2025
- **Accurate prediction of absolute prokaryotic abundance from DNA concentration.** *Cell reports methods*  
Wirbel, J., Andermann, T. M., Brooks, E. F., Evans, L., Groth, A., Dvorak, M., Chakraborty, M., Palushaj, B., Reynolds, G. Z., Porter, I. E., Al Malki, M., Rezvani, A., Gooptu, et al  
2025: 101030
- **Graft-versus-host disease prophylaxis shapes T cell biology and immune reconstitution after hematopoietic cell transplant.** *medRxiv : the preprint server for health sciences*  
Siegel, S. J., DeWolf, S., Schmalz, J., Saber, W., Dong, J., Martens, M. J., Logan, B., Albanese, A., Iovino, L., Chen, E., Kaminski, J., Neuberg, D., Hebert, et al  
2025
- **Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703.** *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*  
Holtan, S. G., Bolaños-Meade, J., Al Malki, M. M., Wu, J., Kitko, C. L., Reshef, R., Rezvani, A. R., Shaffer, B. C., Solh, M. M., Yao, J. M., Runaas, L., Elmariah, H., Larkin, et al  
2025: JCO2400921
- **Comparison of Outcomes of Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Older Versus Younger Patients** *CANCERS*  
Adoncecchi, G., Kumar, A., Mogilli, K., Faramand, R., Liu, H., Khimani, F., Mishra, A., Nieder, M., Nishihori, T., Hansen, D., Jain, M., Lazaryan, A., Perez, et al  
2025; 17 (2)
- **JAK2/mTOR inhibition fails to prevent acute GVHD despite reduced Th1/Th17 cells: final phase 2 trial results** *BLOOD*  
Pidala, J., Holtan, S. G., Walton, K., Kim, J., Cao, B., Elmariah, H., Mishra, A., Bejanyan, N., Nishihori, T., Khimani, F., Perez, L., Faramand, R. G., Davila, et al  
2024; 144 (22): 2295-2307
- **Superiority of Post-Transplant Cyclophosphamide-Based Graft Versus Host Disease (GvHD) Prophylaxis in Patients 70 Years and Older: A BMT CTN 1703 Post-Hoc Analysis**  
Abedin, S., Lian, Q., Martens, M. J., Malki, M., Elmariah, H., Gooptu, M., Larkin, K. T., Shaffer, B. C., Loren, A. W., Solh, M. M., Alousi, A. M., Jamy, O., Yao, et al  
ELSEVIER.2024: 1042-1044
- **Melphalan Dose in Combination With Fludarabine Affects Gastrointestinal Toxicity and Graft-Versus-Host Disease After Allogeneic Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndromes** *TRANSPLANTATION AND CELLULAR THERAPY*  
Albanyan, O., Elmariah, H., Kalos, D., Kim, J., Faramand, R., Sallman, D., Mishra, A., Sweet, K., Perez, L., Ochoa-Bayona, J., Nieder, M., Komrokji, R., Lancet, et al

2024; 30 (11): 1090.e1-1090.e10

- **Low Risk of Relapse and Favorable Survival after Allogeneic Transplantation with Fludarabine and Melphalan Conditioning for Measurable Residual Acute Myeloid Leukemia**  
Babu, A., Bower, K., Siraj, M., Cao, B., Kim, J., Elmariah, H., Faramand, R., Mirza, S., Perez, L., Mishra, A., Khimani, F., Ochoa-Bayona, J. L., Nieder, et al  
ELSEVIER.2024: 4881-4882
- **Similar Cardiac Toxicity Following Allogeneic Hematopoietic Cell Transplant (alloHCT) with Post-Transplant Cyclophosphamide Versus Calcineurin Inhibitor-Based Graft-Versus-Host Disease Prophylaxis**  
Vazquez-Martinez, M. A., Caprice, T., Amisha, F., Almaraz, A., Kim, J., Cao, B., Alomar, M. E., Khimani, F., Mishra, A., Nieder, M., Lazaryan, A., Ochoa-Bayona, J. L., Nishihori, et al  
ELSEVIER.2024: 4871-4872
- **Non-Engrafting CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) Achieves Remissions in Transplant-Naive Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)**  
Elmariah, H., Kim, J., Reid, K., Cubitt, C., Kuykendall, A. T., Lancet, J. E., Komrokji, R. S., Sallman, D., Padron, E., Chan, O., Sweet, K. L., Walker, A. R., Ribickas, et al  
ELSEVIER.2024: 2071-2073
- **Outcomes of Haploidentical Stem Cell Transplant Recipients With HHV-6B Reactivation** *OPEN FORUM INFECTIOUS DISEASES*  
Handley, G., Yepes, A., Eliassen, E., Dominguez, G., Pasikhova, Y., Klinskova, O., Baluch, A., Febres-Aldana, A. J., Alsina, M., Elmariah, H., Khimani, F., Hansen, D. K., Freeman, et al  
2024; 11 (10): ofae564
- **LARGE-SCALE TCR DEEP SEQUENCING REVEALS A T CELL DIVERSITY BOTTLENECK WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE WITH IMPLICATIONS FOR EFFICACY AND TOXICITY: RESULTS OF THE BMT-CTN 1801 STUDY**  
Kean, L., Siegel, S., Schmalz, J., Bien, S., DeWolf, S., Dong, J., Scheffey, D., Sanders, C., Robins, H., Applegate, K., Bar, M., Chhabra, S., Choi, et al  
SPRINGER NATURE.2024: 12-13
- **Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide** *TRANSPLANTATION AND CELLULAR THERAPY*  
Elmariah, H., Otoukesh, S., Kumar, A., Ali, H., Arslan, S., Dimaggio, E., Gonzalez, R., Shouse, G., Pourhassan, H., Nishihori, T., Faramand, R., Mishra, A., Khimani, et al  
2024; 30 (10): 1019e1-1019e9
- **Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study** *BLOOD ADVANCES*  
Jain, T., Estrada-Merly, N., Salas, M., Kim, S., Devos, J., Chen, M., Fang, X., Kumar, R., Andrade-Campos, M., Elmariah, H., Agrawal, V., Aljurf, M., Bacher, et al  
2024; 8 (16): 4281-4293
- **Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant** *CLINICAL LYMPHOMA MYELOMA & LEUKEMIA*  
Ionescu, F., David, J. C., Ravichandran, A., Sallman, D. A., Sweet, K., Komrokji, R. S., Chan, O., Kuykendall, A., Padron, E., Faramand, R., Bejanyan, N., Khimani, F., Elmariah, et al  
2024; 24 (6): 400-406
- **Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations** *AMERICAN JOURNAL OF HEMATOLOGY*  
Caprice, T., Fan, W., Kim, J., Faramand, R., Mishra, A., Perez, L., Khimani, F., Lazar-yan, A., Ochoa-Bayona, J. L., Liu, H., Jain, M. D., Nieder, M., Anasetti, et al  
2024; 99 (6): 1196-1200
- **Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide** *TRANSPLANTATION AND CELLULAR THERAPY*  
Elmariah, H., Otoukesh, S., Kumar, A., Ali, H., Arslan, S., Shouse, G., Pourhassan, H., Nishihori, T., Faramand, R., Mishra, A., Khimani, F., Fernandez, H., Lazaryan, et al  
2024; 30 (2): e1-e11
- **Association between *CYP3A4*, *CYP3A5* and *ABCB1* genotype and tacrolimus treatment outcomes among allogeneic HSCT patients** *PHARMACOGENOMICS*

- Ho, T. T., Perkins, J. B., Gonzalez, R., Hicks, J., Martinez, R., Duranceau, K., North, B., Kim, J., Teer, J. K., Yao, J., Yoder, S. J., Nishihori, T., Bejanyan, et al  
2024; 25 (1): 29-40
- **Haploidentical donor hematopoietic cell transplantation for myelodysplastic/myeloproliferative overlap neoplasms: results from a North American collaboration** *HAEMATOLOGICA*  
Jain, T., Tsai, H., Elmariah, H., Vachhani, P., Karantanos, T., Wall, S. A., Gondek, L. P., Bashey, A., Keyzner, A., Tamari, R., Grunwald, M. R., Abedin, S., Nadiminti, et al  
2023; 108 (12): 3321-3332
  - **A Novel Composite Endpoint of Toxicity-Free, Progression-Free Survival (TPFS) after CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma**  
Saha, A., Mohty, R., Whiting, J., Flores, K., Kim, J., Nishihori, T., Chavez, J. C., Khimani, F., Hansen, D. K., Perna, F., Liu, H., Shah, B. D., Dam, et al  
ELSEVIER.2023
  - **Large-Scale Post-Transplant TCR Deep Sequencing Reveals a Major T Cell Diversity Bottleneck with Post-Transplant Cyclophosphamide with Implications for Both Efficacy and Toxicity: Results of the BMT CTN 1801 Study**  
Kean, L., Siegel, S. J., Schmalz, J. T., Bien, S. A., Scheffey, D., Sanders, C., Robins, H., Applegate, K., Bar, M., Chhabra, S., Choi, S. W., Clark, W., Das, et al  
AMER SOC HEMATOLOGY.2023
  - **Patient-Reported Outcomes of BMT CTN 1703: A Randomized Phase III Study for Gvhd Prophylaxis - a Quality of Life Evaluation**  
Holtan, S. G., Martens, M. J., Al Malki, M. M., Efebera, Y., Kitko, C. L., Reshef, R., Rezvani, A. R., Shaffer, B. C., Solh, M. M., Yao, J. M., Runaas, L., Elmariah, H., Larkin, et al  
AMER SOC HEMATOLOGY.2023
  - **Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma** *BLOOD ADVANCES*  
Lee, D., Kumar, A., Mohammed, T., Peres, L. C., Alsina, M., Bachmeier, C., Blue, B. J., Brayer, J., Chandrasekhar, S., Cruz, A., De Avila, G., Elmariah, H., Faramand, et al  
2023; 7 (16): 4247-4257
  - **Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis.** *The New England journal of medicine*  
Bolaños-Meade, J., Hamadani, M., Wu, J., Al Malki, M. M., Martens, M. J., Runaas, L., Elmariah, H., Rezvani, A. R., Gooptu, M., Larkin, K. T., Shaffer, B. C., El Jurdi, N., Loren, et al  
2023; 388 (25): 2338-2348
  - **Trends and in-hospital cardiac complications in patients with atrial fibrillation undergoing allogeneic stem cell transplant: A National Inpatient Sample analysis (2002-2019)** *EUROPEAN JOURNAL OF HAEMATOLOGY*  
Din, M., Chowdhury, M., Shahzad, M., Zahid, S., Liaqat, H., Osama, M., Elmariah, H.  
2023; 110 (6): 754-761
  - **Haploidentical Donor Blood or Marrow Transplantation for Myelodysplastic/Myeloproliferative Overlap Neoplasms: Results from a North American Collaboration.** *Research square*  
Jain, T., Tsai, H., Elmariah, H., Vachhani, P., Karantanos, T., Wall, S., Gondek, L., Bashey, A., Keyzner, A., Tamari, R., Grunwald, M., Abedin, S., Nadiminti, et al  
2023
  - **Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies** *BLOOD ADVANCES*  
Saygin, C., Roloff, G., Hahn, C. N., Chhetri, R., Gill, S., Elmariah, H., Talati, C., Nunley, E., Gao, G., Kim, A., Bishop, M., Kosuri, S., Das, et al  
2023; 7 (4): 549-554
  - **NCCN Guidelines Insights: Hematopoietic Cell Transplantation, Version 3.2022.** *Journal of the National Comprehensive Cancer Network : JNCCN*  
Saad, A., Loren, A., Bolanos-Meade, J., Chen, G., Couriel, D., Di Stasi, A., El-Jawahri, A., Elmariah, H., Farag, S., Gundabolu, K., Gutman, J., Ho, V., Hoeg, et al  
2023; 21 (2): 108-115
  - **Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703**  
Holtan, S. G., Hamadani, M., Wu, J., Al Malki, M. M., Runaas, L., Elmariah, H., Rezvani, A. R., Gooptu, M., Larkin, K. T., Shaffer, B. C., El Jurdi, N., H., Loren, A. W., Solh, et al  
AMER SOC HEMATOLOGY.2022: 14-16

- **Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis** *TRANSPLANTATION AND CELLULAR THERAPY*  
Wood, A. C., Perez, A., Arciola, B., Patel, K., Johnson, G., DiMaggio, E., Bachmeier, C. A., Reid, K., Carallo, S., Vargas, M. H., Faramand, R., Chavez, J. C., Shah, et al  
2022; 28 (12): 829.e1-829.e8
- **Sirolimus Results in Similar Outcomes to Tacrolimus for Gvhd Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide**  
Elmariah, H., Otoukesh, S., Kumar, A., Ali, H., Arslan, S., Desai, A., Blackmon, A., Pourhassan, H., Nishihori, T., Faramand, R., Mishra, A., Khimani, F., Fernandez, et al  
ELSEVIER.2022: 7638-7640
- **Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)**  
Elmariah, H., Kim, J., Reid, K. M., Cubitt, C., Kuykendall, A., Lancet, J. E., Komrokji, R. S., Sallman, D. A., Chan, O., Sweet, K., Ribickas, A. J., Faramand, R., Mishra, et al  
ELSEVIER.2022
- **Outcomes of Acute Myeloid Leukemia Relapsed Post-Allogeneic Hematopoietic Stem Cell Transplant Treated with Hypomethylating Agents and Venetoclax Combination: A Single Center Experience**  
Ionescu, F., Sallman, D. A., Sweet, K., Komrokji, R. S., Chan, O., Kuykendall, A., Padron, E., Faramand, R., Bejanyan, N., Khimani, F., Elmariah, H., Pidala, J., Mishra, et al  
ELSEVIER.2022: 1288-1290
- **Outpatient Treatment with Anti-Sars-Cov-2 Monoclonal Antibodies and Remdesivir for COVID19 Infections Demonstrates Encouraging Outcomes in Hematopoietic Stem Cell Transplant Recipients: A Single-Center Experience**  
Ionescu, F., Ajayi, E., Leach, A., Alsina, M., Bejanyan, N., Castaneda-Puglianini, O., Elmariah, H., Freeman, C. L., Hansen, D. K., Jain, M. D., Khimani, F., Lazaryan, A., Liu, et al  
ELSEVIER.2022: 10488-10490
- **Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers**  
Jain, T., Tsai, H., Elmariah, H., Vachhani, P., Karantanos, T., Wall, S. A., Gondek, L. P., Bashey, A., Keyzner, A., Grunwald, M. R., Abedin, S., Nadiminti, K. V. G., Iqbal, et al  
ELSEVIER.2022: 7731-7733
- **Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes**  
Sallman, D. A., Elmariah, H., Sweet, K., Mishra, A., Cox, C. A., Chakaith, M., Semnani, R., Shehzad, S., Anderson, A., Sabzevari, H., Lankford, A., Chan, O., SanchezMolina, et al  
ELSEVIER.2022: 10313-10315
- **Early cytopenias and infections after standard of care idecabtagene vicleucel#in relapsed or refractory multiple myeloma.** *Blood advances*  
Logue, J. M., Peres, L. C., Hashmi, H., Colin-Leitzinger, C., Shrewsbury, A. M., Hosoya, H., Gonzalez, R., Copponex, C., Kottra, K. H., Hovanky, V., Sahaf, B., Patil, S., Lazaryan, et al  
2022
- **Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis with Nonmyeloablative Conditioning for Blood or Marrow Transplantation for Myelofibrosis** *TRANSPLANTATION AND CELLULAR THERAPY*  
Jain, T., Tsai, H., DeZern, A. E., Gondek, L. P., Elmariah, H., Bolanos-Meade, J., Luznik, L., Fuchs, E., Ambinder, R., Gladstone, D. E., Imus, P., Webster, J., Prince, et al  
2022; 28 (5): 259.e1-259.e11
- **Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation** *TRANSPLANTATION AND CELLULAR THERAPY*  
Mirza, A., Tandon, A., Jenneman, D., Cao, S., Brimer, T., Kumar, A., Kidd, M., Khimani, F., Faramand, R., Mishra, A., Liu, H., Nishihori, T., Perez, et al  
2022; 28 (4): 185.e1-185.e7
- **Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide** *TRANSPLANTATION AND CELLULAR THERAPY*  
Otoukesh, S., Elmariah, H., Yang, D., Clark, M. C., Siraj, M., Ali, H., Mogili, K., Arslan, S., Nishihori, T., Nakamura, R., Pidala, J., Marcucci, G., Forman, et al

2022; 28 (2): 111.e1-111.e8

- **Commentary: Target CD34 Cell Dose for Allogeneic Hematopoietic Cell Transplantation: Can We Finally Agree?** *Transplantation and cellular therapy*  
Elmariah, H.  
2022; 28 (2): 59-60
- **A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease** *BLOOD ADVANCES*  
Lazaryan, A., Lee, S., Arora, M., Kim, J., Betts, B., Khimani, F., Nishihori, T., Bejanyan, N., Liu, H., Kharfan-Dabaja, M. A., Locke, F. L., Gonzalez, R., Jain, et al  
2022; 6 (1): 259-269
- **MI-Immune/1801: Lessons from an Ongoing, Multi-Center Trial Involving Biospecimen Collection for Prospective Microbiome and Immune Profiling in Patients Undergoing Reduced Intensity Conditioning Allogeneic HCT**  
Brooks, E., Spahn, A., Waldvogel, S., Howard, A., Bar, M., Bratrude, B., Chhabra, S., Clark, W., Das, S., Horowitz, M. M., Jenq, R. R., Jones, R. J., Levine, et al  
AMER SOC HEMATOLOGY.2021
- **Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes**  
Sallman, D. A., Elmariah, H., Sweet, K., Talati, C., Mishra, A., Cox, C. A., Semnani, R., Shah, R. R., Sabzevari, H., Chakiath, M., Uthuppan, J., Lankford, A., Wang, et al  
ELSEVIER.2021
- **Association between CYP3A4, CYP3A5, and ABCB1 Genotype, Tacrolimus Concentrations, and Outcomes Among Allogeneic Hematopoietic Stem Cell Transplantation Patients**  
Ho, T., Perkins, J., Gonzalez, R., Hicks, J., Nishihori, T., Bejanyan, N., Pidala, J., Elmariah, H.  
ELSEVIER.2021
- **Increased Infections and Delayed CD4<sup>+</sup> T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation** *TRANSPLANTATION AND CELLULAR THERAPY*  
Khimani, F., Ranspach, P., Elmariah, H., Kim, J., Whiting, J., Nishihori, T., Locke, F. L., Perez, A., Dean, E., Mishra, A., Perez, L., Lazaryan, A., Jain, et al  
2021; 27 (11): 940-948
- **Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study** *LEUKEMIA*  
Kunte, S., Rybicki, L., Viswabandya, A., Tamari, R., Bashey, A., Keyzner, A., Iqbal, M., Grunwald, M. R., Dholaria, B., Elmariah, H., Ozga, M., Singh, A., Abedin, et al  
2022; 36 (3): 856-864
- **Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis** *TRANSPLANTATION AND CELLULAR THERAPY*  
Khimani, F., Dutta, M., Faramand, R., Nishihori, T., Perez, A., Dean, E., Nieder, M., Perez, L., Mishra, A., Elmariah, H., Davila, M., Ochoa, L., Alsina, et al  
2021; 27 (7): 620.e1-620.e9
- **Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results** *CLINICAL CANCER RESEARCH*  
Pidala, J., Walton, K., Elmariah, H., Kim, J., Mishra, A., Bejanyan, N., Nishihori, T., Khimani, F., Perez, L., Faramand, R. G., Davila, M. L., Nieder, M. L., Sagatys, et al  
2021; 27 (10): 2712-2722
- **ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation** *TRANSPLANTATION AND CELLULAR THERAPY*  
Hansen, D. K., Kim, J., Thompson, Z., Hussaini, M., Nishihori, T., Ahmad, A., Elmariah, H., Faramand, R., Mishra, A., Davila, M. L., Khimani, F., Lazaryan, A., Sallman, et al  
2021; 27 (3): 256.e1-256.e7
- **Impact of infused CD34<sup>+</sup>stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide** *BONE MARROW TRANSPLANTATION*

- Hany, E., Naqvi, S., Kim, J., Nishihori, T., Mishra, A., Perez, L., Faramand, R., Lazaryan, A., Liu, H. D., Khimani, F., Nieder, M., Anasetti, C., Pidala, et al  
2021; 56 (7): 1683-1690
- **A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation** *BLOOD ADVANCES*  
Bejanyan, N., Pidala, J. A., Wang, X., Thapa, R., Nishihori, T., Elmariah, H., Lazaryan, A., Khimani, F., Davila, M. L., Mishra, A., Faramand, R., Jain, M. D., Ochoa, et al  
2021; 5 (5): 1154-1163
  - **Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors** *BLOOD ADVANCES*  
Grunwald, M. R., Zhang, M., Elmariah, H., Johnson, M. H., St Martin, A., Bashey, A., Battiwalla, M., Bredeson, C. N., Copelan, E., Cutler, C. S., George, B. R., Gupta, V., Kanakry, et al  
2021; 5 (4): 975-983
  - **Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation** *LIFE-BASEL*  
Elmariah, H., Brunstein, C. G., Bejanyan, N.  
2021; 11 (2)
  - **Umbilical cord blood or HLA-haploidentical transplantation: Real world outcomes vs randomized trial outcomes.** *Transplantation and cellular therapy*  
O'Donnell, P. V., Brunstein, C. G., Fuchs, E. J., Zhang, M. J., Allbee-Johnson, M., Antin, J. H., Leifer, E. S., Elmariah, H., Grunwald, M. R., Hashmi, H., Horowitz, M. M., Magenau, J. M., Majhail, et al  
2021
  - **Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead** *JOURNAL FOR IMMUNOTHERAPY OF CANCER*  
Kirtane, K., Elmariah, H., Chung, C. H., Abate-Daga, D.  
2021; 9 (7)
  - **Fludarabine-melphalan Conditioning Results in Favorable leukemia-free Survival after Allogeneic Transplantation in Patients with Active or Measurable Residual AML**  
Bower, K., Siraj, M., Kim, J., Cao, B., Elmariah, H., Perez, L., Mishra, A., Nishihori, T., Khimani, F., Faramand, R., Lazaryan, A., Fernandez, H., Nieder, et al  
SPRINGER NATURE.2020: 292-293
  - **Shortened-Duration Immunosuppressive Therapy after Nonmyeloablative, Related HLA-Haploidentical or Unrelated Peripheral Blood Grafts and Post-Transplantation Cyclophosphamide** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
DeZern, A. E., Elmariah, H., Zahurak, M., Rosner, G. L., Gladstone, D. E., Ali, S., Huff, C., Swinnen, L. J., Imus, P., Borrello, I., Wagner-Johnston, N. D., Ambinder, R. F., Brodsky, et al  
2020; 26 (11): 2075-2081
  - **Delayed CD4+T-Cell but Faster B-Cell Immune Reconstitution after Ptcy-Based Compared to Conventional Gvhd Prophylaxis after Allogeneic Transplantation**  
Ranspach, P., Zhou, J., Pidala, J. A., Nishihori, T., Nieder, M. L., Elmariah, H., Faramand, R., Lazaryan, A., Baluch, A., Mishra, A., Perez, L., Ochoa, L., Liu, et al  
ELSEVIER SCIENCE INC.2020: S308-S309
  - **Impact of TP53 gene Mutation Clearance and Conditioning Intensity on Outcome in MDS or AML Patients Prior to Allogeneic Stem Cell Transplantation**  
Chan, O., Hunter, A., Talati, C., Sallman, D. A., Asghari, H., Song, J., Hussaini, M., Bejanyan, N., Elmariah, H., Kuykendall, A. T., Padron, E., Komrokji, R. S., List, et al  
AMER SOC HEMATOLOGY.2019
  - **Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor**  
Grunwald, M. R., Zhang, M., Elmariah, H., Johnson, M. H., St Martin, A., Bashey, A., Bolanos-Meade, J., Bredeson, C., Copelan, E. A., George, B., Gupta, V., Kanakry, C. G., Mehta, et al  
AMER SOC HEMATOLOGY.2019
  - **Clearance of Somatic Gene Mutations in Patients with Acute Myeloid Leukemia Prior to Allogeneic Hematopoietic Cell Transplantation (HCT) Predicts Outcome**

- Chan, O., Talati, C., Asghari, H., Bejanyan, N., Elmariah, H., Hussaini, M., Khimani, F., Kim, J., Komrokji, R. S., Kuykendall, A. T., Lancet, J. E., List, A. F., Nieder, et al  
AMER SOC HEMATOLOGY.2019
- **Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant**  
Mirza, S., Tandon, A., Jenneman, D., Cao, S., Kumar, A., Kidd, M. R., Khimani, F., Mishra, A., Liu, H. D., Nishihori, T., Perez, L., Bejanyan, N., Pidala, et al  
AMER SOC HEMATOLOGY.2019
  - **Impact of TBI-Based Conditioning Regimen on Outcomes of Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplant: Systematic Review and Meta-Analysis**  
Dutta, M., Mhaskar, R., Elmariah, H., Nishihori, T., Shah, B., Nieder, M., Perez, L., Faramand, R., Pidala, J., Bejanyan, N., Khimani, F.  
AMER SOC HEMATOLOGY.2019
  - **Outcomes of Hematopoietic Cell Transplantation in Acute Promyelocytic Leukemia - a Single Institution Experience**  
Hashmi, H., Lancet, J., Mishra, A., Sweet, K. L., Komrokji, R. S., Fernandez, H. F., Perez, L., Khimani, F., Nieder, M., Elmariah, H., Pidala, J., Bejanyan, N., List, et al  
AMER SOC HEMATOLOGY.2019
  - **Immune-Related Adverse Events Requiring Hospitalization: Spectrum of Toxicity, Treatment, and Outcomes** *JOURNAL OF ONCOLOGY PRACTICE*  
Balaji, A., Zhang, J., Wills, B., Marrone, K. A., Elmariah, H., Yarchoan, M., Zimmerman, J. W., Hajjir, K., Venkatraman, D., Armstrong, D. K., Laheru, D. A., Mehra, R., Ho, et al  
2019; 15 (9): 494-+
  - **Post-transplantation cyclophosphamide to facilitate HLA-haploidentical hematopoietic cell transplantation: Mechanisms and results** *SEMINARS IN HEMATOLOGY*  
Elmariah, H., Fuchs, E. J.  
2019; 56 (3): 183-189
  - **Chronic Myelomonocytic Leukemia: 2018 Update to Prognosis and Treatment** *CURRENT HEMATOLOGIC MALIGNANCY REPORTS*  
Elmariah, H., DeZern, A. E.  
2019; 14 (3): 154-163
  - **Survival of Older Patients with AML and MDS after Allogeneic Hematopoietic Transplantation Is Best Determined By Combining Disease Risk and Comorbidity Indices**  
Asghari, H., Mo, Q., Naqvi, S., Lazaryan, A., Davila, M. L., Nishihori, T., Khimani, F., Mishra, A., Perez, L., Elmariah, H., Liu, H., Nieder, M. L., Fernandez, et al  
ELSEVIER SCIENCE INC.2019
  - **Pan-pseudothrombocytopenia: An unusual case of platelet clumping** *AMERICAN JOURNAL OF HEMATOLOGY*  
Elmariah, H., Shanbhag, S.  
2018; 93 (8): 1113-1114
  - **Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors** *BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION*  
Elmariah, H., Kasamon, Y. L., Zahurak, M., Macfarlane, K. W., Tucker, N., Rosner, G. L., Bolanos-Meade, J., Fuchs, E. J., Wagner-Johnston, N., Swinnen, L. J., Huff, C., Matsui, W. H., Gladstone, et al  
2018; 24 (5): 1099-1102
  - **Immune-related adverse events requiring inpatient management: Spectrum of toxicity, treatment, and outcomes.**  
Balaji, A., Zhang, J., Marrone, K., Elmariah, H., Yarchoan, M., Holdhoff, M., Zimmerman, J. W., Hajjir, K., Armstrong, D., Laheru, D. A., Mehra, R., Ho, W., Reuss, et al  
AMER SOC CLINICAL ONCOLOGY.2018
  - **Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia** *JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK*  
Elmariah, H., Pratz, K. W.  
2017; 15 (7): 959-966

- **The Burden of Burnout: An Assessment of Burnout Among Internal Medicine Residents After the 2011 Duty Hour Changes** *AMERICAN JOURNAL OF MEDICAL QUALITY*  
Elmariah, H., Thomas, S., Boggan, J. C., Zaas, A., Bae, J.  
2017; 32 (2): 156-162
- **Genes Associated with Survival in Adult Sickle Cell Disease**  
Elmariah, H., Garrett, M. E., Soldano, K. L., Ataga, K. I., Eckman, J. R., Telen, M. J., Ashley-Koch, A. E.  
AMER SOC HEMATOLOGY.2014
- **Inferior Vena Cava Filters in Trauma Patients: A National Practice Patterns Survey of US Trauma Centers** *AMERICAN SURGEON*  
Rajasekhar, A., Elmariah, H., Lottenberg, L., Beyth, R., Lottenberg, R., Ang, D.  
2014; 80 (12): 1237-1244
- **Factors associated with survival in a contemporary adult sickle cell disease cohort** *AMERICAN JOURNAL OF HEMATOLOGY*  
Elmariah, H., Garrett, M. E., De Castro, L. M., Jonassaint, J. C., Ataga, K. I., Eckman, J. R., Ashley-Koch, A. E., Telen, M. J.  
2014; 89 (5): 530-535
- **Inferior Vena Cava Filters in Trauma Patients: A National Practice Pattern Survey of US Trauma Centers**  
Rajasekhar, A., Elmariah, H., Ang, D., Lottenberg, L., Beyth, R., Lottenberg, R.  
AMER SOC HEMATOLOGY.2012